Clinical trial · Interventional
Vitamin B6 Can Prevent Hand and Foot Syndrome in Cancer Patients Capecitabine Chemotherapy
A Randomized Trial to Determine if Vitamin B6 Can Prevent Hand and Foot Syndrome in Cancer Patients Treated With Capecitabine Chemotherapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): incomplete enrollment
Summary
Brief summary (as posted)
Capecitabine (Xeloda) a drug in cancer therapy. Its use is limited often by its toxicities. This study is asking if vitamin B6 can prevent one of the common toxicities of xeloda which is numbness and/or rash of the hands and feet, a condition called Hand and Foot syndrome. patients , starting capecitabine chemotherapy for their cancer, will participate in this study at John H. Stroger Jr. Hospital of Cook County. They will be randomized to receive either vitamin B6 or a placebo. investigators and patients will be blinded to the intervention.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hand and Foot Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| placebo | Drug | — | UNRESOLVED |
| Vitamin B 6 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- vitamin B6
- description
- patient receiving xeloda and vitamin B6
- interventionNames
- Drug: Vitamin B 6
- type
- PLACEBO_COMPARATOR
- label
- 2 placebo
- description
- patient receiving xeloda and placebo
- interventionNames
- Drug: placebo
Primary outcomes (1)
- measure
- Incidence of Hand-Foot Syndrome (HFS)
- timeFrame
- 1 year
- description
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Any adult patient starting capecitabine-containing chemotherapy * Has never had capecitabine before * Performance status 0-2 using the ECOG classification * Life expectancy more than 6 months * Agreed to stop any vitamin supplements, apart from vitamin D. * Liver function studies including AST/ALT within 3x upper limit of normal * Signed informed consent must be obtained from participating individuals
References
Publications (0)
Data not yet available